xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06008769</url>
    </required_header>
    <id_info>
      <org_study_id>H23-025</org_study_id>
      <nct_id>NCT06008769</nct_id>
    </id_info>
    <brief_title>Cognitive-Behavioral Therapy for Opioid Use Disorder: A Manualized Pilot Study</brief_title>
    <official_title>Cognitive-Behavioral Therapy for Opioid Use Disorder: A Manualized Pilot Study</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Philadelphia College of Osteopathic Medicine</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Prevention Point Philadelphia</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Philadelphia College of Osteopathic Medicine</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this pilot clinical trial is to test the feasibility of a 12-week manualized&#xD;
        cognitive-behavioral therapy treatment for opioid use disorder in reducing or stopping&#xD;
        illicit opioid use in a community setting. Participants will complete 12 weeks of therapy&#xD;
        with a behavioral health counselor and will complete assessments at baseline and 12 weeks.&#xD;
        Other outcomes include changes in mood and perceptions of recovery-related support after 12&#xD;
        weeks of therapy.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        Cognitive-Behavioral Therapy (CBT) is one of the most well-supported and widely used&#xD;
        psychosocial treatments for substance use disorders (SUDs); however, few studies have&#xD;
        evaluated the efficacy of CBT for opioid use disorder (OUD). This prospective, longitudinal&#xD;
        pilot study (pre-post design) will assess the feasibility of the first manualized CBT&#xD;
        treatment for OUD in adults (N = 20) in a community-based setting (Prevention Point&#xD;
        Philadelphia). This study will utilize clinical (urinalysis), patient-reported, and&#xD;
        provider-reported outcomes (mood, support, feasibility, satisfaction with treatment) over 12&#xD;
        weeks of a manualized cognitive-behavioral treatment for OUD. This prospective, longitudinal&#xD;
        pilot study will evaluate the feasibility of a novel psychotherapy for OUD. This study will&#xD;
        utilize both clinical (urinalysis) and patient or provider-reported (mood, support,&#xD;
        feasibility) outcomes to assess the feasibility of 12 weeks of manualized&#xD;
        cognitive-behavioral treatment for OUD. All study recruitment, consent and intervention&#xD;
        delivery will occur at Prevention Point (2913-15 Kensington Ave, Philadelphia, PA). Outcomes&#xD;
        will include participant-reported treatment satisfaction, as well as EMR-extracted clinical&#xD;
        data (session attendance, urinalysis, mood, demographics, medical information, and&#xD;
        recovery-related support).&#xD;
  &#xD;
        We hypothesize that individuals with OUD will demonstrate a reduction illicit opioid use from&#xD;
        baseline to week 12 as assessed by urinalysis (% change, positive/negative). As a secondary&#xD;
        outcome, use of other substances will also be assessed from baseline to week 12 (e.g.,&#xD;
        alcohol, cocaine). Use of medication for OUD (MOUD; e.g., buprenorphine. methadone) will be&#xD;
        accounted for in analyses.&#xD;
  &#xD;
        We hypothesize that mood and perceptions of recovery-related resources will improve from&#xD;
        baseline to week 12.&#xD;
  &#xD;
        As an exploratory aim, we will evaluate intervention feasibility through electronic medical&#xD;
        record (EMR) data of number of sessions attended over 12 weeks, treatment fidelity&#xD;
        checklists, and a participant survey of treatment satisfaction.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">August 6, 2023</start_date>
    <completion_date type="Anticipated">August 2024</completion_date>
    <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Urinalysis-confirmed Reduction or Elimination of Illicit Opioid Use</measure>
      <time_frame>Baseline, 12 weeks</time_frame>
    </primary_outcome>
    <secondary_outcome>
      <measure>The Patient Health Questionnaire-9 (PHQ-9)</measure>
      <time_frame>Baseline, 12 weeks</time_frame>
      <description>The PHQ-9 is a nine-item instrument (0-3 Likert type scale) for monitoring and measuring depression severity over the past two weeks. The PHQ-9 has strong validity and reliability and is frequently used in clinical settings.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The Brief Assessment of Recovery Capital (BARC-10)</measure>
      <time_frame>Baseline, 12 weeks</time_frame>
      <description>The BARC-10 is a 10-item measure assessing the perceived characteristics and assets and individual develops on their recovery journey. The BARC-10 has high internal consistency (α = .90).</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>The Client Satisfaction Questionnaire-8 (CSQ-8)</measure>
      <time_frame>12 weeks</time_frame>
      <description>The CSQ-8 is a brief, eight-item treatment satisfaction questionnaire.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">20</enrollment>
    <condition>Opioid Use Disorder</condition>
    <arm_group>
      <arm_group_label>12 Week Manualized Cognitive-Behavioral Therapy Intervention</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Participants will receive a once-per-week, 12 week manualized cognitive-behavioral therapy intervention.</description>
    </arm_group>
    <intervention>
      <intervention_type>Behavioral</intervention_type>
      <intervention_name>12 Week Manualized Cognitive-Behavioral Therapy Intervention</intervention_name>
      <description>The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.</description>
      <arm_group_label>12 Week Manualized Cognitive-Behavioral Therapy Intervention</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Patient at Prevention Point Philadelphia&#xD;
  &#xD;
            -  18 years or older&#xD;
  &#xD;
            -  Living with opioid use disorder&#xD;
  &#xD;
            -  Has a goal to reduce or eliminate illicit opioid use&#xD;
  &#xD;
            -  Able to provide informed consent&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Not comfortable receiving psychotherapy in English&#xD;
  &#xD;
            -  Under custodial supervision through the legal justice system (e.g., halfway house&#xD;
               following incarceration, involuntary detention or confinement, status as a &quot;prisoner&quot;)&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Michelle R Lent, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Philadelphia College of Osteopathic Medicine</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Michelle R Lent, PhD</last_name>
      <phone>2158716138</phone>
      <email>michellele@pcom.edu</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Hannah R Callahan, MPH</last_name>
      <phone>2158716628</phone>
      <email>hannahca@pcom.edu</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Prevention Point Philadelphia</name>
        <address>
          <city>Philadelphia</city>
          <state>Pennsylvania</state>
          <zip>19134</zip>
          <country>United States</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Denise Botcheos, LCSW</last_name>
        <phone>215-285-1999</phone>
        <email>deniseb@ppponline.org</email>
      </contact>
      <contact_backup>
        <last_name>Chad Gurdgiel, MSW, LSW</last_name>
        <email>chadgurdgiel@ppponline.org</email>
      </contact_backup>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <reference>
      <citation>Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015 Sep-Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166.</citation>
      <PMID>26406300</PMID>
    </reference>
    <reference>
      <citation>Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. Report No.: (SMA) 04-3939. Available from http://www.ncbi.nlm.nih.gov/books/NBK64245/</citation>
      <PMID>22514846</PMID>
    </reference>
    <reference>
      <citation>Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009. Available from http://www.ncbi.nlm.nih.gov/books/NBK143185/</citation>
      <PMID>23762965</PMID>
    </reference>
    <reference>
      <citation>Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction. J Addict Med. 2016 Mar-Apr;10(2):93-103. doi: 10.1097/ADM.0000000000000193.</citation>
      <PMID>26808307</PMID>
    </reference>
    <reference>
      <citation>Seth P, Scholl L, Rudd RA, Bacon S. Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358. doi: 10.15585/mmwr.mm6712a1.</citation>
      <PMID>29596405</PMID>
    </reference>
    <reference>
      <citation>McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. 2010 Sep;33(3):511-25. doi: 10.1016/j.psc.2010.04.012.</citation>
      <PMID>20599130</PMID>
    </reference>
    <reference>
      <citation>Substance Abuse and Mental Health Services Administration. Behavioral health treatments and services; 2017. Retrieved from https://www.samhsa.gov/treatment. Accessed September 6. 2018.</citation>
    </reference>
    <reference>
      <citation>Beck AT. Cognitive therapy: nature and relation to behavior therapy. Behav Ther. 1970;1(2),184-200.</citation>
    </reference>
    <reference>
      <citation>Ellis A. Reason and Emotion in Psychotherapy. New York, NY: Stuart; 1962.</citation>
    </reference>
    <reference>
      <citation>Festinger DS, Lent MR. Cognitive-Behavioral Therapy (CBT) for the Treatment of Opioid Use Disorder. Trafford Publishing; 2022 Aug 18.</citation>
    </reference>
    <reference>
      <citation>Lent MR, Callahan HR, Womer P, Mullen PM, Shook CB, DiTomasso RA, Felgoise SH, Festinger DS. A mental health professional survey of cognitive-behavioral therapy for the treatment of opioid use disorder. J Clin Psychol. 2021 Jul;77(7):1607-1613. doi: 10.1002/jclp.23170. Epub 2021 May 10.</citation>
      <PMID>33971028</PMID>
    </reference>
    <reference>
      <citation>Moore BA, Barry DT, Sullivan LE, O'connor PG, Cutter CJ, Schottenfeld RS, Fiellin DA. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med. 2012 Sep;6(3):205-11. doi: 10.1097/ADM.0b013e3182596492.</citation>
      <PMID>22614936</PMID>
    </reference>
    <reference>
      <citation>Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O'Connor PG, Schottenfeld RS. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013 Jan;126(1):74.e11-7. doi: 10.1016/j.amjmed.2012.07.005.</citation>
      <PMID>23260506</PMID>
    </reference>
    <reference>
      <citation>Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.</citation>
      <PMID>23734858</PMID>
    </reference>
    <reference>
      <citation>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.</citation>
      <PMID>11556941</PMID>
    </reference>
    <reference>
      <citation>Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007 Nov;22(11):1596-602. doi: 10.1007/s11606-007-0333-y. Epub 2007 Sep 14.</citation>
      <PMID>17874169</PMID>
    </reference>
    <reference>
      <citation>Vilsaint CL, Kelly JF, Bergman BG, Groshkova T, Best D, White W. Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder. Drug Alcohol Depend. 2017 Aug 1;177:71-76. doi: 10.1016/j.drugalcdep.2017.03.022. Epub 2017 May 19.</citation>
      <PMID>28578224</PMID>
    </reference>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 17, 2023</study_first_submitted>
    <study_first_submitted_qc>August 17, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 24, 2023</study_first_posted>
    <last_update_submitted>August 17, 2023</last_update_submitted>
    <last_update_submitted_qc>August 17, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 24, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Opioid-Related Disorders</mesh_term>
      <mesh_term>Substance-Related Disorders</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06008769
  org study id: H23-025
  nct id: NCT06008769
  lead sponsor: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this pilot clinical trial is to test the feasibility of a 12-week manualized
        cognitive-behavioral therapy treatment for opioid use disorder in reducing or stopping
        illicit opioid use in a community setting. Participants will complete 12 weeks of therapy
        with a behavioral health counselor and will complete assessments at baseline and 12 weeks.
        Other outcomes include changes in mood and perceptions of recovery-related support after 12
        weeks of therapy.
  Cognitive-Behavioral Therapy (CBT) is one of the most well-supported and widely used
        psychosocial treatments for substance use disorders (SUDs); however, few studies have
        evaluated the efficacy of CBT for opioid use disorder (OUD). This prospective, longitudinal
        pilot study (pre-post design) will assess the feasibility of the first manualized CBT
        treatment for OUD in adults (N = 20) in a community-based setting (Prevention Point
        Philadelphia). This study will utilize clinical (urinalysis), patient-reported, and
        provider-reported outcomes (mood, support, feasibility, satisfaction with treatment) over 12
        weeks of a manualized cognitive-behavioral treatment for OUD. This prospective, longitudinal
        pilot study will evaluate the feasibility of a novel psychotherapy for OUD. This study will
        utilize both clinical (urinalysis) and patient or provider-reported (mood, support,
        feasibility) outcomes to assess the feasibility of 12 weeks of manualized
        cognitive-behavioral treatment for OUD. All study recruitment, consent and intervention
        delivery will occur at Prevention Point (2913-15 Kensington Ave, Philadelphia, PA). Outcomes
        will include participant-reported treatment satisfaction, as well as EMR-extracted clinical
        data (session attendance, urinalysis, mood, demographics, medical information, and
        recovery-related support).
  
        We hypothesize that individuals with OUD will demonstrate a reduction illicit opioid use from
        baseline to week 12 as assessed by urinalysis (% change, positive/negative). As a secondary
        outcome, use of other substances will also be assessed from baseline to week 12 (e.g.,
        alcohol, cocaine). Use of medication for OUD (MOUD; e.g., buprenorphine. methadone) will be
        accounted for in analyses.
  
        We hypothesize that mood and perceptions of recovery-related resources will improve from
        baseline to week 12.
  
        As an exploratory aim, we will evaluate intervention feasibility through electronic medical
        record (EMR) data of number of sessions attended over 12 weeks, treatment fidelity
        checklists, and a participant survey of treatment satisfaction.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Urinalysis-confirmed Reduction or Elimination of Illicit Opioid Use
  time frame: Baseline, 12 weeks
  measure: The Patient Health Questionnaire-9 (PHQ-9)
  time frame: Baseline, 12 weeks
  description: The PHQ-9 is a nine-item instrument (0-3 Likert type scale) for monitoring and measuring depression severity over the past two weeks. The PHQ-9 has strong validity and reliability and is frequently used in clinical settings.
  measure: The Brief Assessment of Recovery Capital (BARC-10)
  time frame: Baseline, 12 weeks
  description: The BARC-10 is a 10-item measure assessing the perceived characteristics and assets and individual develops on their recovery journey. The BARC-10 has high internal consistency (α = .90).
  measure: The Client Satisfaction Questionnaire-8 (CSQ-8)
  time frame: 12 weeks
  description: The CSQ-8 is a brief, eight-item treatment satisfaction questionnaire.
  arm group label: 12 Week Manualized Cognitive-Behavioral Therapy Intervention
  arm group type: Experimental
  description: Participants will receive a once-per-week, 12 week manualized cognitive-behavioral therapy intervention.
  intervention type: Behavioral
  intervention name: 12 Week Manualized Cognitive-Behavioral Therapy Intervention
  description: The manualized intervention, Cognitive Behavioral Therapy for Opioid Use Disorder, was co-written and developed by the study PI, Dr. Lent (see Appendix). The manual consists of one module (Module 0) on assessment and 12 modules of CBT. This study will focus on delivery of Modules 1-12 that focus on several tenets of CBT, including skill development (cognitive restructuring, refusal skills, problem-solving, coping strategies), functional analysis (triggers, reinforcement) and utilizing the cognitive model.
  arm group label: 12 Week Manualized Cognitive-Behavioral Therapy Intervention
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Michelle R Lent, PhD
  role: Principal Investigator
  affiliation: Philadelphia College of Osteopathic Medicine
  last name: Michelle R Lent, PhD
  phone: 2158716138
  email: michellele@pcom.edu
  last name: Hannah R Callahan, MPH
  phone: 2158716628
  email: hannahca@pcom.edu
  facility: 
  status: Recruiting
  contact: 
  contact backup: 
  country: United States
  citation: Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015 Sep-Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166.
  PMID: 26406300
  citation: Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. Report No.: (SMA) 04-3939. Available from http://www.ncbi.nlm.nih.gov/books/NBK64245/
  PMID: 22514846
  citation: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009. Available from http://www.ncbi.nlm.nih.gov/books/NBK143185/
  PMID: 23762965
  citation: Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction. J Addict Med. 2016 Mar-Apr;10(2):93-103. doi: 10.1097/ADM.0000000000000193.
  PMID: 26808307
  citation: Seth P, Scholl L, Rudd RA, Bacon S. Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358. doi: 10.15585/mmwr.mm6712a1.
  PMID: 29596405
  citation: McHugh RK, Hearon BA, Otto MW. Cognitive behavioral therapy for substance use disorders. Psychiatr Clin North Am. 2010 Sep;33(3):511-25. doi: 10.1016/j.psc.2010.04.012.
  PMID: 20599130
  citation: Substance Abuse and Mental Health Services Administration. Behavioral health treatments and services; 2017. Retrieved from https://www.samhsa.gov/treatment. Accessed September 6. 2018.
  citation: Beck AT. Cognitive therapy: nature and relation to behavior therapy. Behav Ther. 1970;1(2),184-200.
  citation: Ellis A. Reason and Emotion in Psychotherapy. New York, NY: Stuart; 1962.
  citation: Festinger DS, Lent MR. Cognitive-Behavioral Therapy (CBT) for the Treatment of Opioid Use Disorder. Trafford Publishing; 2022 Aug 18.
  citation: Lent MR, Callahan HR, Womer P, Mullen PM, Shook CB, DiTomasso RA, Felgoise SH, Festinger DS. A mental health professional survey of cognitive-behavioral therapy for the treatment of opioid use disorder. J Clin Psychol. 2021 Jul;77(7):1607-1613. doi: 10.1002/jclp.23170. Epub 2021 May 10.
  PMID: 33971028
  citation: Moore BA, Barry DT, Sullivan LE, O'connor PG, Cutter CJ, Schottenfeld RS, Fiellin DA. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. J Addict Med. 2012 Sep;6(3):205-11. doi: 10.1097/ADM.0b013e3182596492.
  PMID: 22614936
  citation: Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O'Connor PG, Schottenfeld RS. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013 Jan;126(1):74.e11-7. doi: 10.1016/j.amjmed.2012.07.005.
  PMID: 23260506
  citation: Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.
  PMID: 23734858
  citation: Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
  PMID: 11556941
  citation: Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med. 2007 Nov;22(11):1596-602. doi: 10.1007/s11606-007-0333-y. Epub 2007 Sep 14.
  PMID: 17874169
  citation: Vilsaint CL, Kelly JF, Bergman BG, Groshkova T, Best D, White W. Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder. Drug Alcohol Depend. 2017 Aug 1;177:71-76. doi: 10.1016/j.drugalcdep.2017.03.022. Epub 2017 May 19.
  PMID: 28578224
  responsible party type: Sponsor
  mesh term: Opioid-Related Disorders
  mesh term: Substance-Related Disorders
  sharing ipd: No